COSTEM 2022 | The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts

Miguel-Angel Perales • 28 Oct 2022

COSTEM 2022

PROGRESS II

Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of T cell selection in ablative matched unrelated donor (MUD) transplants. Despite CD34 selection being inferior to post-transplant cyclophosphamide and tacrolimus as graft-versus-host disease (GVHD) prophylaxis in the PROGRESS II trial (NCT02345850), CD34 selection is still a promising strategy. Reducing cytomegalovirus (CMV) infection as well as administering anti-thymocyte globulin (ATG) based on lymphocyte count pre-conditioning therapy will additionally enhance CD34 selection in patients. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.